ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL

GHEORGHIADE, M., GATTIS, W.A., O CONNOR, C.M., ADAMS, K.F., EL KAYAM, U., BARBAGELATA, A., GHALI, J.K., BENZA, R.L., MCGREW, F.A., KLAPHOLZ, M., OUYANG, J., & ORLANDI, C.. (2004). ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL. JOURNAL OF AMERICAN MEDICAL ASSOCIATION (JAMA), 291(8), 1963-1971. SID. https://sid.ir/paper/540287/en

GHEORGHIADE M., GATTIS W.A., O CONNOR C.M., ADAMS K.F., EL KAYAM U., BARBAGELATA A., GHALI J.K., BENZA R.L., MCGREW F.A., KLAPHOLZ M., OUYANG J., ORLANDI C.. ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL. JOURNAL OF AMERICAN MEDICAL ASSOCIATION (JAMA)[Internet]. 2004;291(8):1963-1971. Available from: https://sid.ir/paper/540287/en

M. GHEORGHIADE, W.A. GATTIS, C.M. O CONNOR, K.F. ADAMS, U. EL KAYAM, A. BARBAGELATA, J.K. GHALI, R.L. BENZA, F.A. MCGREW, M. KLAPHOLZ, J. OUYANG, and C. ORLANDI, “ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL,” JOURNAL OF AMERICAN MEDICAL ASSOCIATION (JAMA), vol. 291, no. 8, pp. 1963–1971, 2004, [Online]. Available: https://sid.ir/paper/540287/en